This is the first study to evaluate the safety profile of multiple HTX-019 infusions in patients with cancer” Calcanes and Vacirca (2019).
Abstract:
HTX-019 is a neurokinin 1 receptor antagonist approved for prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients with cancer receiving moderately and highly emetogenic chemotherapy. When administered as a 30-minute intravenous (IV) infusion, HTX-019 has displayed a tolerable and favorable safety profile in healthy subjects. This is the first study to evaluate the safety profile of multiple HTX-019 infusions in patients with cancer. This retrospective analysis shows that HTX-019 administered via IV infusion has a favorable safety profile in patients with cancer, and no new treatment-emergent adverse events were identified.
You may also be interested in…
[rp4wp]
Reference:
Calcanes, G. and Vacirca, J.L. (2019) Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis. Journal of Infusion Nursing. 42(5), p.260-263. doi: 10.1097/NAN.0000000000000341.